Subcutaneous Injection Articles & Analysis
21 news found
FDA-approved Comirnaty, 113-O12B showed significantly lower mRNA expression in the liver and higher expression in the lymph nodes after subcutaneous injection. Another example is FPD-Lipid Nanoparticles (Catalog: CDCLP24-003-L). ...
Gantenerumab was well tolerated, including the subcutaneous administration. The GRADUATE Phase 3 program evaluated the safety and efficacy of gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia over 27 months. 1,965 study participants across 30 countries were randomized 1:1 to receive gantenerumab or placebo by ...
Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. ...
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, ...
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
” Today, biologics are predominantly delivered via injection or intravenous infusion, which limits long-term treatment adherence, often leading to suboptimal patient outcomes. ...
” TikoMed’s phase II open label clinical trial conducted at Sahlgrenska University Hospital in Gothenburg, Sweden, evaluated the safety, tolerability and possible efficacy of subcutaneous injections of ILB in the treatment of thirteen patients (of both sexes) with ALS of intermediate severity. ...
Together, the partners aim at transforming the administration of injectable medicines and improving the patient’s experience, especially for those with chronic diseases. Portal develops technology which allows for needle-free and high-speed subcutaneous injection of medicine and – via connectivity –adherence monitoring along ...
Dupixent is also approved in one or more of these indications in more than 60 countries around the world, and more than 400,000 patients have been treated globally. Dupixent is an injection under the skin (subcutaneous injection) at different injection sites. ...
Asthma: injection site reactions, pain in the throat (oropharyngeal pain), high count of a certain white blood cell (eosinophilia), and parasitic (helminth) infections. ...
Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. ...
Upgrading Bevacizumab from IV to subcutaneous (SubQ) administration may now be possible with Qprotyn's HILOPRO technology. ...
The trial will assess the safety, tolerability and immunogenicity of an MR vaccine delivered using Micron’s technology, compared with delivery via standard subcutaneous injection, in adults and children. The Company-sponsored Phase 1/2 trial will be conducted at the Medical Research Council Unit The Gambia (“MRCG”) under the leadership of Ed ...
Injectable testosterone is usually prescribed intramuscularly, though studies have shown that subcutaneous injections are just as effective at maintaining testosterone levels as the intramuscular ...
TIKOMED’s study, conducted at the School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, UK is the first to demonstrate that subcutaneous injections of ILB®, which has already demonstrated safety in humans, can resolve inflammation and arising/established fibrosis in both rodent and human models of inflammation and ...
tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). tiakis’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene ...
Our Phase IIa clinical trial evaluating the safety, tolerability and possible efficacy of subcutaneous injections of ILB® in ALS is finalized and has been reported to the Swedish Medical Products Agency. ...
By coupling a daily oral care activity with allergy immunotherapy, OMIT, delivered using Allerdent®, can help address the issues associated with poor adherence that limits the use and effectiveness of other forms of allergy immunotherapy, such as subcutaneous injections. Allovate® retains the global rights to develop products based on the OMIT platform ...
tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). ...